麻豆传媒

Shail Maingi, MD (she/her) is a medical oncologist, hematologist, and palliative care physician at the Dana-Farber Cancer Institute South Shore location. In addition to seeing patients with solid tumors and blood diseases, she is the inaugural DFCI Network Health Equity and Inclusion Liaison. Dr. Maingi has been a health equity advocate and clinical researcher for years, with a focus on health care disparities in oncology and end-of-life settings, particularly for sexual and gender minority people and with a focus on intersectionality.  She is currently part of the scientific program committee for the American Society of Clinical Oncology (ASCO) annual conference and serves on ASCO’s Diversity and Inclusion Committee, Practice Health Task Force, and as the co-chair of their Sexual and Gender Minority Task Force. Dr. Maingi was also the founding chair of the American Academy of Hospice and Palliative Medicine’s LGBTQ Special Interest Group. She serves on the GLMA: Health Professionals Advancing LGBTQ Equality board and heads their Racial Justice Task Force, after serving as their VP for the Lesbian Health Fund for 6 years. 

Dr. Sarmad Sadeghi earned his medical degree at Tehran University of Medical Sciences. He has a Master of Science degree (MS) in Health Information Sciences and a Doctor of Philosophy degree (PhD) in Public Health Management and Policy Sciences from the University of Texas Health Sciences Center at Houston.
He completed his internal medicine residency at the University of Texas Medical School at Houston and the Cleveland Clinic Foundation. He completed his hematology/oncology fellowship at the Cleveland Clinic Taussig Cancer Institute. Dr. Sadeghi joined the faculty at the division of oncology of University of Southern California in 2013 and has a clinical and research focus in genitourinary malignancies, specifically bladder, kidney and prostate cancers.
Dr. Sadeghi is the study chair and principal investigator of a number of multicenter clinical trials and is also an active member of SWOG cooperative group and the California Cancer Consortium.
Dr. Sadeghi is well published with several original articles and abstracts in peer reviewed journals and international meetings.

Dr. Jayachandran specializes in Breast Medical Oncology. She is an Assistant Professor of Clinical Medicine at Keck and also serves as the Director of Breast Medical Oncology and Genomics at the LAC+USC Medical Center. She graduated from Stanford University and the University of Michigan Medical School before completing her residency in Internal Medicine at UCSF Fresno and fellowship in Hematology/Oncology at USC. She is active in research with a focus on clinical trials, translational studies, biomarkers, and improving access to care. She enjoys teaching fellows, residents, and medical students.

Dr. Manz graduated from Duke University School of Medicine in 2012. He received his training in internal medicine at the Hospital of the University of Pennsylvania from 2012-2015, and subsequently worked as a hospitalist in oncology at the same hospital until 2017. After completing fellowship in hematology/oncology and a Masters of Science in Health Policy Research at the University of Pennsylvania, he joined Dana-Farber in GI Oncology and the Department of Population Sciences 2020.

Dr. Jänne received his MD and PhD from the University of Pennsylvania in 1996. He completed postgraduate training in internal medicine at Brigham and Women's Hospital and in medical oncology at DFCI in 2001. He is the Senior Vice President for Translational Medicine and the Scientific Director of the Belfer Center for Applied Cancer Science. His main research interests include studying the therapeutic relevance of oncogenic alterations in lung cancer. He was one of the co-discoverers of epidermal growth factor receptor (EGFR) mutations and has led the development of therapeutic strategies for patients with EGFR mutant lung cancer.




 

Dr. Marianna Koczywas has been a staff physician at City of Hope Comprehensive Cancer Center since 2001, specializing in thoracic oncology and diseases of the lungs, including .
She is part of the lung cancer and head and neck cancer teams at City of Hope, which is a world leader in the  and research of several serious diseases. The goal is providing patients with the opportunity to live longer and much better lives.
“For patients who have just been told they have cancer, I want them to know there is a place they can come, either for treatment or to get the best opinion,” Koczywas said. “At City of Hope, we have a great team of people where these patients can receive the best possible care.”
Koczywas is the principal investigator in several ongoing , including two specifically involving . She also is an outspoken advocate for combining  with cancer treatment programs early in the process.
She received her degree in 1984 from the Medical Academy of Lodz, in Lodz, Poland, then did a residency at St. Francis Medical Center in Pittsburgh. Koczywas first came to City of Hope for fellowships that included the Department of Medical Oncology & Therapeutics Research and the Department of Hematology/Bone Marrow Transplantation.

Zoe Larned, MD, is a breast medical oncologist at Ochsner MD Anderson Cancer Center in New Orleans. She is board certified in internal medicine and oncology, and specializes in hematology-oncology. She has a medical interest in solid tumors, breast cancer and genitourinary cancer, which includes cancers of the kidneys, bladder and urethra, as well as reproductive organs.
Dr. Larned is a member of the Ochsner Neuroendocrine Tumor, or NET, multidisciplinary team, one of the nation’s largest NET programs and a leader in the diagnosis and management of all forms of neuroendocrine tumors. 
She earned a medical degree from Emory University in Atlanta, where she also completed an internship and residency in internal medicine. She completed a hematology-oncology fellowship at Duke University Medical Center in Durham, North Carolina.